Presentation Article Template

Date: 21 Dec 2018 

  • Key pointer of Presentation
  • Key Pointer of Presentation

SUMMARY OF PRESENTATION & OTHER INFO, a clinical-stage immunotherapy company focused on autologous and off-the-shelf, allogeneic therapies for cancer patients, today announced that Dr. George W. Sledge, Jr., M.D., Professor and Chief of Medical Oncology at Stanford University Medical Center, will join Tessa’s Board of Directors as an independent director, effective 2 January 2019.

 

***

Tessa Therapeutics Media Contacts

Gladys Wong
gladyswong@tessatherapeutics.com
+65 6384 0755

Will Carnwath, Ben Fry
TessaTherapeutics@brunswickgroup.com
+65 6426 8188

About Tessa Therapeutics

Tessa Therapeutics is a clinical-stage immunotherapy company focused on the development of autologous and off-the-shelf, allogeneic therapies for cancer patients.

Tessa’s Virus-Specific T cell (VST) platform harnesses the body’s potent anti-viral immune response and has shown compelling results in the treatment of solid tumors.

Tessa is building a portfolio of innovative, next-generation therapies by combining the qualities of VSTs with other immuno-oncology technologies. This includes a rapidly growing pipeline of clinical and pre-clinical autologous programs that target a wide range of viral and non-viral cancers, including nasopharyngeal carcinoma (NPC), cervical cancer, oropharyngeal cancer, liver cancer and lung cancer. In addition, Tessa is leveraging its platform to develop an allogeneic therapy to address Epstein-Barr virus (EBV)-associated lymphoproliferative diseases.

Tessa has built up robust operational and supply chain capabilities to successfully deliver T cell therapy treatments to a large patient pool worldwide. Together with the Company’s academic, clinical, and commercial research partners, Tessa has created a fully-integrated approach to the treatment of cancer with immunotherapy. For more information on Tessa, please visit www.tessatherapeutics.com.